TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00470691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plaster cast
Description: complete circular plaster cast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dorsal splint
Description: dorsal plaster splint
Study: NCT04067583

Intervention type: OTHER
Intervention: Physician questionnaire
Description: This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
Study: NCT03310320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0284 oral solution 2.5 mg/mL
Description: AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AZD0284 oral solution, twice daily for 4 weeks
Study: NCT03198039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Isha Kriya (IK) meditation approximately 12 minutes, twice a day
Study: NCT00669162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20mg/m2 IV weekly for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex and Zoladex (or Lupron)
Description: Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
Study: NCT03168503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGG+Promitor™
Description: synbiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor™
Description: Soluble Corn Fiber
Study: NCT02726867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: Treatment will consist of LEV 4000 mg i.v. over 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lacosamide
Description: Treatment will consist of LCM 600 mg i.v. over 10 minutes
Study: NCT03168503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGG-PB12+Promitor™
Description: synbiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control
Study: NCT01161420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspire Upper Airway Stimulation System
Description: Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
Study: NCT03123315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Illuminating Catheter
Description: This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
Study: NCT04006782

Intervention type: DEVICE
Group type: OTHER
Intervention: Narrow dental implants
Description: Insertion of narrow dental implants in multiple fixed prosthesis
Study: NCT04290390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Segesterone Acetate and Ethinyl Estradiol
Description: Contraceptive Vaginal System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Segesterone Acetate and Ethinyl Estradiol
Description: Contraceptive Vaginal System
Study: NCT03552484

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program
Description: Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care/Online Survey
Description: Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
Study: NCT04169815

Intervention type: DIAGNOSTIC_TEST
Intervention: Access Immunodiagnostic Products
Description: Access Natriuretic Peptide Assay
Study: NCT02496104

Intervention type: BEHAVIORAL
Intervention: Package n°1 of the APIB

Intervention type: BEHAVIORAL
Intervention: Package n°1 of the APIB
Study: NCT02726867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Treatment will consist of KET 2.5 mg/kg over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
Study: NCT02725255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ujiplus
Description: Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: 400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: uji
Description: maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
Study: NCT02021968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV-TV003
Description: TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN2∆30-7169
Description: The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2∆30-7169
Description: The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
Study: NCT04290390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Segesterone Acetate and Ethinyl Estradiol
Description: Contraceptive Vaginal System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: CYP3A inducer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: CYP3A inhibitor
Study: NCT00626054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG solution in a single dose of 3 liters
Description: Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG solution
Description: PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
Study: NCT02033460

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Education
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
Study: NCT04428281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
Study: NCT02033460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Education
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
Study: NCT03285529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATIFIX
Description: STRATIFIX symmetric PDS Plus; Stratifix knotless suture

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VICRYL
Description: Vicryl #1
Study: NCT01416181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo in part 1
Study: NCT01332032

Intervention type: BEHAVIORAL
Intervention: Reminder Letter
Description: A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram

Intervention type: BEHAVIORAL
Intervention: Reminder Call
Description: A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.

Intervention type: BEHAVIORAL
Intervention: Counselor Call
Description: Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
Study: NCT04286308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological data collection
Description: Electrophysiological data collection at the time of DBS surgery.
Study: NCT01399346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Application of 18 IU insulin aspart as one bolus at one injection site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
Study: NCT02812680

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
Study: NCT04556604

Intervention type: BEHAVIORAL
Intervention: Educational meetings and visual prompts
Description: Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts

Intervention type: BEHAVIORAL
Intervention: Educational meetings and visual prompts
Description: Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
Study: NCT01821963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Starting dose: 180 mcg subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Starting dose: 1,000 mg by mouth daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Starting dose: 750 mg by mouth 3 times a day.
Study: NCT02428140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Reveal LINQ

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorin Spiderflash-t
Study: NCT03604614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Without Hyperthermic Intraperitoneal Chemotherapy
Description: The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
Study: NCT02351037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Subjects will receive ibrutinib 560 mg once daily on a continuing basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + LD-AraC
Description: Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
Study: NCT04428281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
Study: NCT03520972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 75ug
Description: 60 eligible patients will be included in this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 150ug
Description: 60 eligible patients will be included in this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 200ug
Description: 60 eligible patients will be included in this group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 60 eligible patients will be included in this group
Study: NCT00106223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
Study: NCT01229800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate(NaP) solution
Description: Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
Study: NCT04206267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceledent
Description: Device for accelerating tooth movement
Study: NCT03705117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V565
Description: Capsules for oral administration
Study: NCT01571024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 40 mg, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
Study: NCT01860573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino acids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Study: NCT02978131

Intervention type: OTHER
Intervention: Histopathological study

Intervention type: OTHER
Intervention: Molecular study (Polymerase chain reaction)
Study: NCT04426903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: webFitForAll
Description: PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: webFitForAll
Description: PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
Study: NCT02351037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib+Azacitidine
Description: Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).